Naito S
Dept. of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Gan To Kagaku Ryoho. 1996 May;23(6):684-8.
Indication and new agents for endocrine therapy in prostate cancer were outlined, and new development of endocrine therapy was reviewed in terms of total androgen blockade (TAB) for advanced disease and localized disease as neoadjuvant setting, and antiandrogen withdrawal syndrome. TAB is considered to be useful in the treatment of patients with advanced prostate cancer, particularly those with minimal disease and good performance status. Neoadjuvant TAB therapy before radical prostatectomy may decrease cancer positive surgical margins. However, long-term follow-up data are required to determine the impact on survival. Antiandrogen withdrawal seems to be therapeutically efficacious for patients with hormone-refractory prostate cancer, with a response rate of about 20%. Therefore, antiandrogen withdrawal should be tried before initiating therapy for hormone-refractory prostate cancer.
概述了前列腺癌内分泌治疗的适应证和新药物，并从晚期疾病的全雄激素阻断（TAB）和作为新辅助治疗的局限性疾病以及抗雄激素撤药综合征方面回顾了内分泌治疗的新进展。TAB被认为对晚期前列腺癌患者的治疗有用，特别是那些疾病轻微且身体状况良好的患者。根治性前列腺切除术前行新辅助TAB治疗可能会降低癌阳性手术切缘。然而，需要长期随访数据来确定对生存的影响。抗雄激素撤药似乎对激素难治性前列腺癌患者有治疗效果，缓解率约为20%。因此，在开始激素难治性前列腺癌治疗前应尝试抗雄激素撤药。
